• Liver-focused Ambys launches with $140M, Takeda partnership fiercebiotech
    August 09, 2018
    Third Rock Ventures is debuting Ambys Medicines, which will develop cell and gene therapies as well as drugs for chronic liver diseases. Ambys starts life with $140 million in committed capital, including $100 million from Takeda, part of which came in th
PharmaSources Customer Service